Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Galderma confirms price range for blockbuster IPO
(Sharecast News) - Galderma announced the price range for its forthcoming flotation on Wednesday, leaving the skincare giant on track to raise more than £2bn. The Swiss firm, which owns sensitive skin brand Cetaphil, among others, has announced a price range of between 49 to 53 Swiss francs.
The offering consists of 40.5m new shares, 277,000 existing shares and an over-allotment option of up to 6.1m existing shares. If fully exercised, the offer size will be 2.3bn Swiss francs (£2.1bn).
Galderma first announced plans to debut on the Swiss stock exchange earlier this month, in what is likely to be one of the biggest IPOs in Europe this year.
Proceeds will be used to pay down debt.
The firm is owned by Swedish private equity firm EQT, Singapore's CIC and the Abu Dhabi Investment Authority. EQT will sell down a proportion of its stake as part of the IPO, although it has confirmed it will remain a "significant" investor.
Galderma is one of the world's largest dermatology companies. Last year it saw sales jump nearly 9%, excluding currency fluctuations, to a record $4.1bn. Core operating profits rose 21% to $942m. Its specialist products range from acne treatments to wrinkle fillers.
Originally a joint venture between Nestle and L'Oréal, the EQT-led consortium acquired the Zug-based business in 2019 in a $10bn deal.
The offer period will run until 20 March.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
